CYB5R3 and cancer: We suppose that high “therapeutic” intracellular concentration of ascorbate in cancer cells is then likely to induce “enzyme (Cyb5R3) end-product inhibition” – a negative feedback, regulating any enzymatic pathway (Fig. 4).